MedTrace Logo

EverolimuS-ElUtinG BioresorbAble VasculaR Scaffolds vErsus EVerolimus-Eluting Stents in Patients With Diabetes Mellitus

NCT02632292 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2019-09-26

No results posted yet for this study

Summary

Prospective, randomized, controlled, multicenter, open-label study to compare everolimus-eluting bioresorbable vascular scaffolds to everolimus-eluting stents in patients with diabetes mellitus.

Conditions

Interventions

DEVICE

Absorb GT1

Bioresorbable vascular scaffold

DEVICE

Promus

Everolimus-eluting stent

Sponsors & Collaborators

  • University Hospital Schleswig-Holstein

    collaborator OTHER

  • Kerckhoff Klinik

    collaborator OTHER

  • Charite University, Berlin, Germany

    collaborator OTHER

  • University of Luebeck

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2017-01-03
Completion
2017-01-03

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02632292 on ClinicalTrials.gov